Home / Resource Library / DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Results of a study examining CD19 CAR T therapy for treatment of relapsed diffuse large b-cell lymphoma.